5 million and growing: scaling Granudacyn® production in Salzburg
Mölnlycke® has reached a significant milestone with the production of 5 million units of its Granudacyn® wound irrigation solution at its manufacturing site in Salzburg, Austria, reflecting strong and sustained global demand for advanced wound cleansing solutions.
“The consistent growth we’ve seen for Granudacyn® enables us to take a long-term, targeted approach to expanding our manufacturing capacity,” said Kevin Sands, General Manager of the Salzburg site. “By optimising processes, investing in equipment and applying lean principles, we are increasing output while maintaining the highest standards of quality and reliability.”
Mölnlycke acquired the Salzburg factory in October 2024 after more than five years of collaboration with its previous owners. Since then, it has been successfully integrated into Mölnlycke’s global manufacturing network of 16 sites in 11 countries, with investments in systems, operational excellence and cross-functional collaboration driving greater efficiency, scalability and growth.
Granudacyn® is a biocompatible, non-cytotoxic wound irrigation solution designed to safely cleanse, irrigate and moisten a wide range of acute, chronic and contaminated wounds. Using hypochlorous acid-based technology, it supports wound healing while ensuring microbial purity of the solution and ease of use. The product is suitable for a broad range of indications, including pressure injuries, leg and foot ulcers, burns (1st and 2nd degree) and surgical wounds.
Today, Granudacyn® is available in 54 markets worldwide, having expanded significantly beyond its European origins. Commercial momentum continues to build and, following FDA clearance, Granudacyn® is now being introduced in the United States, with further market expansion planned.
“Granudacyn® plays an important role in opening up broader conversations around modern wound care and our wider portfolio,” said Giuseppe Conti, Global Product Manager for Granudacyn®. “Its flexibility across multiple wound types, combined with strong clinical confidence, has driven adoption across a growing number of markets.”
With production continuing to scale, Mölnlycke remains committed to supporting healthcare professionals worldwide with reliable access to high-quality wound care solutions that reduce the burden of wounds, improve patient outcomes and enhance clinical efficiency.
Latest news
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China. -
Simple glove change could save the NHS £45 million over five years and improve caesarean safety
Gothenburg, Sweden. 27 April 2026. A new study1 published in the Journal of Hospital Infection shows that introducing a simple glove change during caesarean birth could deliver millions in cost savings for the National Health Service (NHS) in England.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.
-
Europe faces a growing chronic wound crisis – time to act is now
Gothenburg, Sweden. 31 March 2026. Mölnlycke®, a global leader in MedTech, today welcomes the publication of Shaping the future of wound care in Europe, the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group. The wound paper highlights the growing burden of chronic wounds and urges EU policymakers to elevate wound care as a strategic health priority across the EU.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.